The global single-use bioreactors market is projected to reach USD 1,085.7 million by 2021 from USD 408.4 million in 2016, growing at a CAGR of 21.6% during the forecast period (2016–2021). In this report, the single-use bioreactors market is broadly segmented on the basis of product type, cell type, technology, application, end user, and region. Factors such as improved return on investment for small companies and startups, reduced complexity in automation, and positive impact on the environment are driving the growth of the single-use bioreactors market.
On the basis of cell type, the single-use bioreactors market is categorized into mammalian cells, bacteria, yeast, and other cells (insect and plant cells). In 2016, the monoclonal antibodies segment is expected to account for the largest share of the single-use bioreactors market. Factors such as reduced risk of contamination and easy implementation in bioproduction are driving the adoption of SUBs for the production of these molecules. Based on technology, the single-use bioreactors market is categorized into wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others technologies. The wave-induced motion SUBs segment is expected to account for the largest market share in 2016. Growth in this segment can be attributed to the advantages offered by this technology such as high flexibility and shorter lead times.
Product launches was the most widely adopted growth strategy pursued by players in the single-use bioreactors market, to increase their shares and cater to the unmet needs. The major players operating in the single-use bioreactors market include Sartorius Stedim Biotech S.A. (France), Merck Millipore (Germany), GE Healthcare (U.S.), Danaher Corporation (U.S.), and Thermo Fisher Scientific Inc. (U.S.).
Related Reports: Biotechnology Market Research Reports